Novel Therapy Could Help People with Asthma, COPD, Cystic Fibrosis, and Cancer-Related Lung Disease; Experimental Drug Reduces Airway Mucus That Exacerbates Common Lung Diseases

A multicenter research team co-led by The University of Texas MD Anderson Cancer Center has developed the first drug to treat the uncontrolled secretion of mucins in the airways, which causes potentially life-threatening symptoms in millions of Americans with asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), as well as lung disease resulting from cancer and cancer treatment. The study was published on March 23, 2022 in Nature. The open-access article is titled “Inhibition of Calcium-Triggered Secretion by Hydrocarbon-Stapled Peptides.”

Login Or Register To Read Full Story